KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Income from Non-Controlling Interests: 2017-2025

Historic Income from Non-Controlling Interests for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $15.8 million.

  • Amneal Pharmaceuticals' Income from Non-Controlling Interests rose 32.32% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.7 million, marking a year-over-year increase of 36.19%. This contributed to the annual value of $43.0 million for FY2024, which is 21.94% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Income from Non-Controlling Interests of $15.8 million as of Q3 2025, which was up 19.48% from $13.2 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Income from Non-Controlling Interests registered a high of $17.8 million during Q2 2023, and its lowest value of -$119.3 million during Q2 2022.
  • In the last 3 years, Amneal Pharmaceuticals' Income from Non-Controlling Interests had a median value of $11.9 million in 2024 and averaged $10.9 million.
  • Its Income from Non-Controlling Interests has fluctuated over the past 5 years, first crashed by 776.00% in 2022, then soared by 5,034.11% in 2023.
  • Amneal Pharmaceuticals' Income from Non-Controlling Interests (Quarterly) stood at -$14.1 million in 2021, then surged by 89.17% to -$1.5 million in 2022, then surged by 447.87% to $5.3 million in 2023, then surged by 94.89% to $10.3 million in 2024, then skyrocketed by 32.32% to $15.8 million in 2025.
  • Its Income from Non-Controlling Interests was $15.8 million in Q3 2025, compared to $13.2 million in Q2 2025 and $12.4 million in Q1 2025.